Table 3.

Adverse drug reaction (ADR) frequency related to anthroposophic medicinal product (AMP) characteristics

AMP characteristic	ADRs		MDADsa	ADRs/MDADsa
	N	%	N
Route of administration
Local (cutaneous, ophthalmic, rectal, other)	2900	52.7	1802	1.61
Parenteral (injectables)	1539	28.0	82	18.85
Oral	1060	19.3	1789	0.59
Unknown	7	0.1	n.a.b	n.a.b
Total	5506	100.0	3672	1.50
Concentration
Non-diluted	3795	68.9	1907	1.99c
D1–D3 dilution	1097	19.9	1393	0.79c
≥ D4 dilution	431	7.8	310	1.39c
Othere	176	3.2	63	2.81c
Unknown	7	0.1	n.a.b	n.a.b
Total	5506	100.0	3672	1.50
Starting material
Botanical	2680	48.7	1831	1.46d
Zoological	92	1.7	33	2.77d
Chemical	51	0.9	153	0.33d
Mineral	12	0.2	38	0.32d
Vegetabilized metalf	18	0.3	8	2.13d
More than one starting material	1646	29.9	872	1.89d
Compositions	1004	18.2	737	1.36d
Unknown	3	0.1	n.a.b	n.a.b
Total	5506	100.0	3672	1.50

MDADs maximum daily administration doses sold

^a× 1 million

^bn.a. not applicable, sales volumes could not be calculated for unknown origin of route of administration, and unknown concentration or starting material

^cCalculated as number of ADRs/MDAD per category of AMP concentration

^dCalculated as number of ADRs/MDAD per category of starting material

^eMixture of different dilution categories in one AMP

^fHerbs cultivated with specially prepared and diluted metals